A 101 - Aclaris Therapeutics

Drug Profile

A 101 - Aclaris Therapeutics

Alternative Names: A-101 - Aclaris; V-101 - Aclaris

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator Aclaris Therapeutics
  • Class Skin disorder therapies
  • Mechanism of Action Oxidoreductase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Seborrhoeic keratosis

Highest Development Phases

  • Phase III Seborrhoeic keratosis
  • Phase II Warts

Most Recent Events

  • 01 Dec 2016 Aclaris Therapeutics completes a phase II trial in Warts in USA (NCT02669862)
  • 15 Nov 2016 Top-line efficacy and adverse events data from the two phase III SEBK 301 and SEBK 302 trials in Seborrheic keratosis released by Aclaris Therapeutics
  • 01 Oct 2016 Aclaris Therapeutics completes a phase III trial for Seborrhoeic keratosis in USA before July 2016(Topical) (NCT02667288)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top